Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Opdivo-Avastin Combo Hits Goal in Non-Squamous NSCLC; Ono Prepping for Japan Filing
August 4, 2020
- Takeda to Merge Shire Japan in October
August 4, 2020
- JCR to Start Global Study of MPS I Med; Japan Launch Planned in September
August 4, 2020
- JCR to Boost Manufacturing Capacity for Temcell by 30%
August 4, 2020
- BMS Japan to Integrate Celgene Next Year, HQ Relocation Planned in H1 2022: Chief
August 3, 2020
- Daiichi Sankyo Sales Skid 4.9% on Coronavirus, Price Cuts; Enhertu, Edoxaban Upbeat
August 3, 2020
- Takeda Ups Full-Year Profit Guidance after EU Clears Obligation to Divest SHP647
August 3, 2020
- Shionogi Suffers Double-Digit Dip on Q1 Earnings as COVID-19 Weighs
August 3, 2020
- Ono’s Q1 Operating Profit Up 35% as SGA, R&D Costs Decrease on COVID-19
August 3, 2020
- Pevonedistat Granted FDA’s Breakthrough Therapy Status for Higher-Risk MDS: Takeda
August 3, 2020
- Sumitomo Dainippon’s Q1 Sales Up 13.9% on Equa/EquMet Contribution
August 3, 2020
- Kyowa Kirin’s 1H Sales Up 4.2% Driven by Overseas Biz; Full-Year Guidance Down on Slack Nesp AG, COVID-19
August 3, 2020
- JCR in Talks with AstraZeneca on COVID-19 Vaccine Solution Manufacturing
August 3, 2020
- Ono Drops ONO-5334 for COVID-19, Pursues Foipan Project
July 31, 2020
- Teva Takeda Deal Aimed at Boosting Efficiency, Quality: Nichi-Iko Chief
July 31, 2020
- Teva Takeda Narrowing Focus on Unique Generics, Eyes Innovative Meds: CEO
July 31, 2020
- Nichi-Iko Pulls Out from Avigan Contract Manufacturing
July 31, 2020
- 28 Products from 10-Plus Firms Recalled due to Flawed Tests at Kyowa CritiCare
July 31, 2020
- Sumitomo Dainippon Files Japan NDA for Poxel’s Diabetes Med
July 31, 2020
- Eisai Seeks Lenvima’s Label Expansion into Thymic Carcinoma
July 31, 2020
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…